AI Article Synopsis
- Influenza virus cases in Canada dropped significantly during the COVID-19 pandemic but began to rise again in spring 2022 as restrictions eased.
- The Canadian Sentinel Practitioner Surveillance Network found that the 2021/22 vaccine was only 36% effective against late-season influenza A(H3N2) infections, which were notably different from the vaccine strain.
- These results support the World Health Organization's decision to modify the 2022/23 northern hemisphere vaccine to better target the emerging A(H3N2) clade 3C.2a1b.2a.2 strain.
Article Abstract
Influenza virus circulation virtually ceased in Canada during the COVID-19 pandemic, re-emerging with the relaxation of restrictions in spring 2022. Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network reports 2021/22 vaccine effectiveness of 36% (95% CI: -38 to 71) against late-season illness due to influenza A(H3N2) clade 3C.2a1b.2a.2 viruses, considered antigenically distinct from the 3C.2a1b.2a.1 vaccine strain. Findings reinforce the World Health Organization's decision to update the 2022/23 northern hemisphere vaccine to a more representative A(H3N2) clade 3C.2a1b.2a.2 strain.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511683 | PMC |
| http://dx.doi.org/10.2807/1560-7917.ES.2022.27.38.2200720 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!